Elipta Rechargeable Battery Outdoor LED Table Lamp - Black or White (White)

Product Information

Paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with a short-acting inhaled bronchodilator. Relvar Ellipta should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. Your doctor will explain how you should use your Trelegy Ellipta inhaler. They’ll also explain how much to use and how often. You’ll typically take one inhalation each day, at about the same time each day.

Trelegy Ellipta contains three active drugs: fluticasone (an inhaled corticosteroid), umeclidinium (an anticholinergic), and vilanterol (a type of LABA). Trelegy Ellipta and alcohol Keep in mind that having COPD or asthma can make it harder to be physically active. This can contribute to weight gain. Asthma is a condition caused by swelling and narrowing of your airways and lungs. Symptoms can include:If you don’t understand something related to your condition or treatment, ask your doctor to explain it to you. Umeclidinium bromide demonstrated a statistically significant greater improvement from baseline in weighted mean FEV 1 over 0-6 hours post-dose at week 12 compared with placebo (166 ml, p<0.001) in the 12-week pivotal study. Umeclidinium bromide demonstrated a greater improvement from baseline in weighted mean FEV 1 over 0-6 hours post-dose at week 24 compared with placebo (150 ml, p<0.001 *) in the 24-week pivotal study. Following repeat dosing of fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (up to three-fold as measured by AUC (0–24)) in subjects with hepatic impairment (Child-Pugh A, B or C) compared with healthy subjects. The increase in fluticasone furoate systemic exposure in subjects with moderate hepatic impairment (Child-Pugh B; fluticasone furoate/vilanterol 184/22 micrograms) was associated with an average 34% reduction in serum cortisol compared with healthy subjects. Dose-normalised fluticasone furoate systemic exposure was similar in subjects with moderate and severe hepatic impairment (Child-Pugh B or C).

Administration of umeclidinium bromide may produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs treatment should be discontinued immediately and alternative therapy instituted if necessary. Fluticasone furoate/vilanterol should be administered with caution in patients with pulmonary tuberculosis or in patients with chronic or untreated infections. In HZA106837 the risk of experiencing a severe asthma exacerbation in patients receiving fluticasone furoate/vilanterol 92/22 micrograms was reduced by 20% compared with FF 92 micrograms alone (hazard ratio 0.795, p=0.036 95% CI 0.642, 0.985). The rate of severe asthma exacerbations per patient per year was 0.19 in the FF 92 group (approximately 1 in every 5 years) and 0.14 in the fluticasone furoate/vilanterol 92/22 micrograms group (approximately 1 in every 7 years). The ratio of the exacerbation rate for fluticasone furoate/vilanterol 92/22 micrograms versus FF 92 was 0.755 (95% CI 0.603, 0.945). This represents a 25% reduction in the rate of severe asthma exacerbations for subjects treated with fluticasone furoate/vilanterol 92/22 micrograms compared with FF 92 (p=0.014). The 24-hour bronchodilator effect of fluticasone furoate/vilanterol was maintained throughout a one-year treatment period with no evidence of loss in efficacy (no tachyphylaxis). Fluticasone furoate/vilanterol 92 /22 micrograms consistently demonstrated 83 mL to 95 mL improvements in trough FEV 1 at weeks 12, 36 and 52 and Endpoint compared with FF 92 micrograms (p<0.001 95% CI 52, 126 mL at Endpoint). Forty four percent of patients in the fluticasone furoate/vilanterol 92/22 group were well controlled (ACQ7 ≤0.75) at end of treatment compared to 36% of subjects in the FF 92 micrograms group (p<0.001 95% CI 1.23, 1.82). But some research has shown that heavy drinking can worsen your lung function over time. If you drink alcohol and you have chronic obstructive pulmonary disease (COPD) or asthma, it’s best to avoid drinking large amounts.For more information about this side effect, see the “Side effect focus” section below. Side effect focus Talk with your doctor if you’re concerned about hair loss with any medications you take. Is Trelegy Ellipta similar to alternative drugs, such as Advair and Spiriva?

Pharmacotherapeutic group: Drugs for obstructive airway diseases, anticholinergics, ATC code: R03BB07 Fluticasone furoate/vilanterol should not be used to treat acute asthma symptoms, for which a short-acting bronchodilator is required. Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.

Therapeutic indication

A randomised, double-blind, parallel group, 24 week study (201378) was conducted to demonstrate non-inferiority (using a margin of -100 mL for trough FEV 1) of fluticasone furoate/vilanterol 92/22 once daily to salmeterol/FP 50/250 twice daily in adults and adolescents whose asthma was well controlled following 4 weeks of treatment with open-label salmeterol/FP 50/250 twice daily (N=1504). Subjects randomised to once-daily FF/VI maintained lung function comparable with those randomised to twice-daily salmeterol/FP [difference in trough FEV 1 of +19 mL (95% CI: -11, 49)]. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. Oral corticosteroids can cause weight gain, especially if they’re taken long term. One example of this type of drug is prednisone (Rayos). Patients should not stop therapy with fluticasone furoate/vilanterol in asthma, without physician supervision since symptoms may recur after discontinuation. Will I need to use Trelegy Ellipta long term? It’s possible. You’ll use Trelegy Ellipta long term if you and your doctor agree that it’s safe and effective for you.